Table 2 Univariate Cox’s regression analysis of prognostic factors for overall survival (N = 40)
Parameter | Univariate | |
|---|---|---|
HR (95% CI) | p value | |
ECOG, per point | 2.8 (1.6–4.7) | < 0.001 |
Bone metastases, yes versus no | 7.3 (2.6–20.5) | < 0.001 |
Brain metastases, yes versus no | 12.5 (2.5–69.6) | 0.004 |
Total tumor volume, per 100 cm3 | 1.6 (1.2–2.1) | 0.005 |
Pulmonary metastases, yes versus no | 0.4 (0.2–0.8) | 0.011 |
Locoregional tumor volume, per 100 cm3 | 1.5 (1.0–2.2) | 0.029 |
Total metastases volume, per 100 cm3 | 2.5 (1.1–5.7) | 0.031 |
Radiotherapy dose, BED10 per 10 Gy | 0.8 (0.7–1.0) | 0.052 |
Number of involved organ systems | 0.4 (0.1–1.3) | 0.110 |
Time interval from OMD diagnosis to first local treatment, months | 0.8 (0.6––1.1) | 0.170 |
Number of metastases | 0.8 (0.6–1.1) | 0.189 |
Systemic treatment, yes versus no | 1.6 (0.8–3.3) | 0.229 |
Cetuximab, yes versus no | 1.7 (0.6–4.5) | 0.298 |
Distant nodal metastases, yes versus no | 0.7 (0.3–1.6) | 0.341 |
PET Staging | 0.7 (0.3–1.6) | 0.398 |
Hepatic metastases, yes versus no | 0.6 (0.2–2.0) | 0.407 |
Duration of local treatments for OMD, months | 0.9 (0.8–1.1) | 0.454 |
Age, per 10 years | 1.2 (0.8–1.7) | 0.460 |
Metachronous versus synchronous OMD | 0.8 (0.4–1.6) | 0.502 |
Checkpoint inhibitor treatment, yes versus no | 1.6 (0.4–6.6) | 0.553 |
Active locoregional tumor manifestation | 1.2 (0.6–2.6) | 0.574 |
Platin combination chemotherapy, yes versus no | 0.9 (0.5–2.0) | 0.859 |